FY2028 Earnings Estimate for JNJ Issued By Leerink Partnrs

Johnson & Johnson (NYSE:JNJ) – Analysts at Leerink Partnrs issued their FY2028 earnings per share estimates for shares of Johnson & Johnson in a research note issued on Tuesday, May 13th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings of $12.77 per share for the year. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.58 per share. Leerink Partnrs also issued estimates for Johnson & Johnson’s FY2029 earnings at $13.98 EPS.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion.

A number of other equities research analysts have also weighed in on JNJ. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. The Goldman Sachs Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Finally, Barclays reduced their price target on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Trading Up 1.2%

Shares of JNJ stock opened at $151.37 on Friday. The firm has a market capitalization of $364.20 billion, a P/E ratio of 22.76, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock’s fifty day simple moving average is $156.27 and its 200 day simple moving average is $153.90.

Institutional Trading of Johnson & Johnson

A number of institutional investors and hedge funds have recently modified their holdings of JNJ. Pacifica Partners Inc. grew its holdings in Johnson & Johnson by 17.1% during the fourth quarter. Pacifica Partners Inc. now owns 35,046 shares of the company’s stock valued at $5,047,000 after purchasing an additional 5,111 shares during the period. Fiduciary Financial Group LLC grew its holdings in Johnson & Johnson by 5.8% during the fourth quarter. Fiduciary Financial Group LLC now owns 4,370 shares of the company’s stock valued at $621,000 after purchasing an additional 240 shares during the period. Wynn Capital LLC grew its holdings in Johnson & Johnson by 1.4% during the fourth quarter. Wynn Capital LLC now owns 12,647 shares of the company’s stock valued at $1,829,000 after purchasing an additional 178 shares during the period. Accurate Wealth Management LLC grew its holdings in Johnson & Johnson by 8.4% during the fourth quarter. Accurate Wealth Management LLC now owns 23,214 shares of the company’s stock valued at $3,298,000 after purchasing an additional 1,806 shares during the period. Finally, SeaCrest Wealth Management LLC grew its holdings in Johnson & Johnson by 1.5% during the fourth quarter. SeaCrest Wealth Management LLC now owns 25,087 shares of the company’s stock valued at $3,628,000 after purchasing an additional 374 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.